Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.

@article{Kizaki2018InfliximabES,
  title={Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.},
  author={Kazuha Kizaki and Fumiharu Yamashita and Tomoya Hayashi and Noboru Funakoshi},
  journal={International journal of rheumatic diseases},
  year={2018},
  volume={21 10},
  pages={
          1815-1821
        }
}
AIM This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well-controlled patients as C-reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well-controlled patients with RA. METHODS We recruited 61 well-controlled (CRP < 0.3 mg/dL within normal ranges) patients with RA using biological agents… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 25 references

The thiol pool

  • L Turell, R Radi, B Alvarez
  • 2013

Serum level

  • M Hirao, N Yamasaki, H Oze
  • 2012

Sub - clinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis : the CARRE Study

  • AM vanSijl, IA vandenOever, MJ Peters
  • Ann Rheum Dis
  • 2012

Similar Papers

Loading similar papers…